Trial Profile

Ranolazine for the Prevention of Recurrent Persistent Atrial Fibrillation After Electrical Cardioversion: a Pilot Study.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 02 May 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ranolazine (Primary)
Indications Atrial fibrillation
Focus Therapeutic Use
Acronyms GILEAD

Most Recent Events

16 Mar 2017 Status changed from recruiting to discontinued.
08 Aug 2012 Actual initiation date changed from 1 Jan 2012 to Mar 2012 as reported by ClinicalTrials.gov.
08 Aug 2012 Planned End Date changed from 1 Oct 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com